In the protocol, “Multi-center, Randomized, Double-blind, Placebo-controlled, Exploratory Study to Evaluate the Efficacy and Safety of HAD-B1 for Dose-finding in EGFR positive and locally advanced or metastatic NSCLC subjects who need Afatinib therapy”,[1] which appeared in Volume 99, Issue 49 of Medicine, the authors would like to note the following updates to the protocol. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.